Skip to main content
. Author manuscript; available in PMC: 2013 Oct 21.
Published in final edited form as: Int J Neuropsychopharmacol. 2012 Jul 25;16(2):477–483. doi: 10.1017/S1461145712000685

Fig. 1.

Fig. 1

Increased BDNF signalling by the D5R in rodent PFC. (a) Representative blots depicting the effects of a single injection of the PLC-lined dopamine agonist SKF 83959 on CaMKIIα, pCaMKIIα, BDNF, TrkBfull, TrkB.T1, and GAD67 in rat PFC 90 minutes post injection (n=8–9 rats/group). GAPDH was used as a loading control. (b) SKF 83959 (1.5 mg/kg) increased total expression levels of CaMKIIα but did not alter phosphorylation of CaMKIIα at Thr286. (c) Expression of BDNF was elevated following SKF 83959, with no changes in the total expression levels of TrkBfull and TrkB.T1. (d) An increase in the ratio of TrkBfull:TrkB.T1, an index of receptor signalling, was evident following SKF 83959 administration. (e) SKF 83959 increased GAD67 expression in rat PFC. (f) Increased BDNF and GAD67 expression in D1R−/− mice, but not D5R−/− mice, following SKF 83959 (3 mg/kg) administration (n=6–7 mice/group). (g) Increased basal GAD67 expression in D1R−/− mice. Representative blots are also shown. Bars shown represent means ± s.e.m. and, with the exception of the TrkBfull:TrkB.T1 ratio, are expressed as a percentage of saline-treated controls. *P<0.05, ** P<0.01.